1	Bioinformatics and machine learning-based identification of cell cycle-related
2	genes and molecular subtypes in endometrial cancer
3	Jingying Pan ^{a,b,1} , Shuhan Huang ^{c,1} , Bidong Fu ^{c,1} , Ruiyu Zhang ^b , Minqin Zhou ^c ,
4	Zichuan Yu ^c , Hong Zeng ^c , Xitong Geng ^c , Yanting Zhu ^d , Hao Zheng ^c , Hao Wan ^b ,
5	Xiaoyu Qu ^e , Shengwei Tang ^c , Yanying Zhong ^{a*}
6	^a .Department of Obstetrics and Gynecology, Second Affiliated Hospital of Nanchang
7	University, Nanchang, China;
8	^b First College of Clinical Medicine, Nanchang university, China;
9	^{c.} Second College of Clinical Medicine, Nanchang university, China;
10	^{d.} HuanKui Academy, Nanchang University, China;
11	^{e.} School of Ophthalmology&optometry,Nanchang University, China.
12	
13	
14	¹ These authors contributed equally to this work.
15	*Correspondence: Yanying Zhong, E-mail:qqqaz012@163.com, Department of
16	Obstetrics and Gynecology, Second Affiliated Hospital of Nanchang University,
17	Nanchang, China. 1 Minde Road, Nanchang, Jiangxi Province, 330000, China;
18	
19	
20	
21	

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Abstract

Endometrial cancer is a common malignant tumor in women, with rising incidence 24 25 rates and an unoptimistic prognosis. DSN1 is a kinetochore protein-coding gene that affects centromere assembly and progression in cell cycles, which is associated with 26 adverse predictions for many cancers. However, the role of DSN1 in UCEC has not 27 yet been reported. We identified the UCEC-related gene module and obtained the 28 differential genes. Then we constructed a diagnostic model and identified the subtype 29 of the molecule and its association with predictions. Subsequently, we identified 30 31 DSN1 as the core gene and predicted its predictive value. Furthermore, using bioinformatics methods, we found DSN1 was associated with certain clinical 32 characteristics and experimentally validated the expression in cancer tissues of DSN1. 33 34 Pathway enrichment analysis identified DSN1 as a cell cycle-associated protein, which was validated by WB. The protein interaction network also revealed DSN1 was 35 significantly associated with NDC80. Then we explored the correlation of DSN1 and 36 immune cells and immune cell infiltration and found that DSN1 may affect Th2 37 enrichment by affecting CCL7 and CCL8. Drug susceptibility analysis showed DSN1 38 was sensitive to cisplatin and resistant to sunitinib. In conclusion, DSN1 was a novel 39 biomarker that contributes to prognosis and treatment. 40

41

42 Introduction

Endometrial cancer (UCEC) is the fourth most familiar cancer in women (1). The
morbidity of UCEC has increased by 132% in the last three decades, and the mortality

45 rate has also increased (2, 3). Most patients with early-stage endometrial cancer are relatively manageable by the hysterectomy and adjuvant radiotherapy (4). However, 46 47 the current prognosis for terminal UCEC patients remains poor, with a five-year survival rate of only 15% for stage IV patients (5). Although chemotherapy is the 48 standard treatment for patients with terminal or relapsing endometrial cancer, the 49 outcome is unsatisfactory (6). So there is still a need to find ways to assist in 50 pre-diagnosis to ameliorate the prognosis of UCEC. Biomarkers play a significant part 51 in the identification, early diagnosis, and disease prevention and monitoring during 52 53 treatment. Therefore, it is significant to find biomarkers that can enhance the prognosis of endometrial cancer and assist in early diagnosis. 54

DSN1(DSN1 component of MIS12 kinetochore complex) is a widely distributed 55 56 protein in the centromere, and its coding gene is located on chromosome 20q11.23. DSN1 plays a vital part in many biological processes, for example, mitosis and cell 57 cycle. Some studies have indicated that chromosomal instability is connected with the 58 high expression of DSN1. And chromosomal instability can lead to chromosomal 59 structural and quantitative abnormalities, which is a prominent feature of human 60 cancers. DSN1 has been reported to have profound significance in the progression of 61 various tumors, including breast carcinoma (7), colorectal carcinoma (8), 62 hepatocellular carcinoma (9), and sarcoma (10). For example, in colorectal and 63 hepatocellular carcinomas, DSN1 affects cell cycle progression and is closely related 64 to its clinicopathological features, and in vitro, DSN1 significantly promotes 65

osteosarcoma cell proliferation (11). However, the function of DSN1 in UCEC hasnot been reported.

With the bioinformatics and experimental method, we investigated the potential 68 function and mechanism of DSN1 in UCEC. By the LASSO regression and consensus 69 70 cluster analysis, we confirmed the core genes and determined the molecular subtypes of UCEC and their relationship with prognosis. Then, survival and random forest 71 analysis were utilized to identify the key gene, DSN1. The expression of DSN1 in 72 UCEC and its correlation with prognosis were analyzed by R software, gRT-PCR, and 73 74 Western Blot experiments. Subsequently, Linkedomics and GSEA were utilized to investigate the pathway enrichment and latent biological functions of DSN1 and 75 verified by WB. Using STRING, we constructed a DSN1 protein interaction 76 77 network. In addition, the relationship between DSN1 and tumor-infiltrating immune cells, chemokines, and drug interactions in UCEC were also investigated. Our study 78 suggested that DSN1 is a novel biomarker of UCEC that contributes to prognosis and 79 80 treatment.

81

82 Materials and methods

83 Clinical samples

The specimens of all 50 patients from the Second Affiliated Hospital of Nanchang University were pathologically identified with UCEC between December 2023 and September 2024. While the tissues were still fresh, total proteins were removed. The study was approved by the ethics committee of Nanchang University's Second

Affiliated Hospital (No. Review [2023] No. (165)). This is a retrospective study. As it analyzed existing medical records and archived samples, obtaining informed consent was infeasible. The ethics committee of Nanchang University's Second Affiliated Hospital has approved the waiver of informed consent for this clinical research. And after the data is collected, information can be obtained that can identify individual participants.

94 Data Collection and Proceed

95 Sequencing and clinicopathological data of UCEC patients were derived from the
 96 TCGA database (https://cancergenome.nih.gov), including 59 normal samples and

- 97 554 tumor samples. The mRNA expression profiles (Number: GSE17025, GSE39099,
- 98 and GSE106191) were derived from the GEO database
 99 (https://www.ncbi.nlm.nih.gov/geo/).
- 100 Determination of differentially expressed genes (DEGs)

101 The gene sets were normalized, and difference analysis was carried out using the

¹⁰² "limma" package to get DEGs between each comparison group and the control group.

103 We used a P-value less than 0.05 and $|\log 2$ fold change (FC) |> 1 to determine DEGs.

104 Cell culture

105 The commercially accessible UCEC cell line HEC-1-B was utilized to matrix cells,

106 while the detailed method can be referred to in this article (12).

107 Transfection with shRNA

108 Specific sequences were designed to manipulate the expression of DSN1. ShRNAs 109 were cloned into the lentiviral pLKO.1 vector, which was purchased commercially

110 from GenePharma Biothch in Shanghai, China.

111 **RNA extraction and qRT-PCR**

The TRIzol reagent (Invitrogen, USA) per the manufacturer's instructions was applied to isolate total RNA from the cells. Invitrogen's M-MLV reverse transcription kit was used to do reverse transcription on total RNA. The Agilent Technologies AriaMx Real-Time PCR System (Agilent, USA) and SYBR Green PCR Master Mix (Roche, Switzerland) were utilized for the qRT-PCR analysis. The relative expression was computed using the 2 (delta delta threshold cycle) (2Ct) technique with tubulin as a normalized internal control.

119 Western blotting analysis and antibodies

120 Western blotting analysis was carried out. Primary antibodies included anti-DSN1

121 (1:1000, Cell Signaling Technology 4724), anti-NDC80 (1:1000, Santa Cruz,

122 sc-515550), anti-Cyclin D1 monoclonal antibody (1:1000, Abcam, ab16663),

anti-Tubulin monoclonal antibody (1:1000, Proteintech, 11224-1-AP).

124 WGCNA (Weighted correlation network analysis)

Using WGCNA, we uncovered interesting gene modules that are closely connected to other genes. First, transpose the concatenated matrix file, then screen out the genes with expression variance in the first quartile before constructing the correlation matrix. The weighted adjacency matrix is then transformed into a topological overlap matrix (TOM) to assess network connectivity, and the hierarchical clustering approach is utilized to create the TOM clustering tree. Genes were sorted into modules based on their expression patterns using a weighted correlation coefficient.

- 132 The relationship between modules and clinical characteristics was further investigated
- to identify modules linked with UCEC for investigation.
- 134 Gene function enrichment analysis

GSEA was implemented by applying R package ClusterProfiler 4.1.0, and genomic 135 enrichment analysis of differentially expressed genes of TCGA and GEO was 136 performed. Prominent functional and pathway differences between high and low 137 DSN1 expression groups were also analyzed by GSEA. Based on gene expression 138 profiles and phenotypic grouping, we kept the minimum gene set at 5 and the largest 139 140 gene set at 5,000. p values less than 0.05 and FDR less than 0.1 were deemed statistically significant. Then, R packages "clusterProfiler" and "org.hh.egg.db" were 141 applied to gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes 142 143 (KEGG) analysis to further analyze the associated pathways of 164 genes and 20 genes in UCEC. An adjusted p-value of less than 0.05 was considered significantly 144 enriched. 145

146 Machine learning identification of candidate genes associated with UCEC

Using the least absolute shrinkage and selection operator (LASSO), the final core genes were screened. A diagnostic model was applied to determine a risk score for each patient. The random forest algorithm is an algorithm based on bagging. Bagging is an integration method that randomly divides a data set into multiple subsets to build a basic decision tree. We used a random forest algorithm to score these genes.

152 Identification of molecular-related subtypes by consensus clustering

153 The samples are categorized by determining the consensus matrix through

154 consensus clustering, and the K-value for the number of clusters is set between 2 and 155 9. The optimal K value was determined when the cumulative distribution function 156 index reached an approximate maximum. Correlated subtypes were established based 157 on consensus clustering of 20 gene expression levels. These results were used to 158 define Cluster 1, Cluster 2, and Cluster 3. Heat maps were plotted using the ggplot2 159 software package to visualize the expression of these 20 genes in the different 160 clusters.

161 LinkedOmics Database Analysis

The LinkedOmics database (http://www.linkedomics.org/login.php) was used to evaluate 32 TCGA cancer-related datasets. Its "LinkFinder" module has been used to investigate differential expression genes associated with DSN1 in the TCGA UCEC. If the P-value and false discovery rate are both less than 0.05, the gene will be considered a significant related gene.

167 **Protein-protein interaction network construction**

The STRING database (https://string-db.org) allows us to explore the genomic relationships between genes encoding proteins and thus infer the biological activity of proteins. Our study utilized the STRING database to explore the top 500 co-expressed DSN1 genes and selected medium-confidence genes with a confidence level of 0.9, which were then displayed by Cytoscape software to generate an overall PPI network.

173 **TIMER Database Analysis**

174 The Tumor Immune Estimation Resource (TIMER) database could provide175 immune infiltration information for different cancer types systematically. We utilized

176 "Gene", "Diff Exp", and "Correlation" modules to acquire immune-related177 information and gene expression level information.

178 **TISIDB analysis**

179 The TISIDB database (http://cis.hku.hk/TISIDB/) could be used to investigate the

association between individual genes and immunity in the setting of cancer. Using the

181 "Chemokine" module, we investigated the link between DSN1 expression and

182 cytokines in UCEC.

183 **Comparative toxicogenomics database**

184 The CTD (http://ctdbase.org/) integrates the interactions of specific genes with

relevant compounds and contains literature coverage of a number of compounds.

186 From this, we got several drugs that regulate DSN1 expression.

187 Statistical Analysis

In this study, all statistical studies were accomplished by R software (version 3.6.3/4.0.3/4.1.2).

190 Survival and clinicopathological features analysis

The R packages involved are "pROC", "timeROC" and "ggplot2". By using logistic regression, we investigated the association between DSN1 and clinicopathological features. In addition, DSN1 and the prognostic model use the "Survival" software package for survival regression fitting. And survival analysis for different subgroups. Then, to compare various survival factors, our team developed time-dependent receiver operating characteristic curves (ROC) and used the "rms" package to build a nomogram model and visualize it.

198 Correlation analysis

- 199 Using the R tools (limma, ggplot2, and heatmap packages), we conducted gene
- 200 expression correlation analysis. The correlation of DSN1 with DSN1-related genes.
- 201 The correlation of CCL7 and CCL8 with Th2 cells.

202 Calculation of immune infiltration

- We used R-packet GSVA and 24 immune cell markers to calculate the immune infiltration corresponding to DSN1.
- 205
- 206 **Result**

207 Modular cluster analysis of endometrial cancer-related genes using weighted 208 gene co-expression network analysis (WGCNA).

209 Aimed to explore critical modules and genes linked with endometrial cancer (UCEC), we used the mRNA expression matrix of TCGA-UCEC, GSE17025, 210 GSE39099, and GSE106191. First, we identified 3922 and 9037 differential genes for 211 GEO (P-value <0.05) and TCGA (P-value<0.05, FDR<0.05, and |logFC|>1)(Figure 212 1A-B), which were then used for functional enrichment analysis and WGCNA. The 213 GSEA analysis revealed significant links between UCEC-related differential genes 214 and cell cycle regulation and immunological pathways (Figure 1C, D). We then 215 separately constructed the WGCNA model and identified the gene co-expression 216 modules (Figure 1E, F). We found that the yellow modules containing 371 genes were 217 most relevant to the UCEC for the TCGA-UCEC database, while it contained 429 218 genes for the GEO. Furthermore, we conducted a cross-analysis of the genes and 219

220 obtained a set of 164 genes (Figure 1G), which was analyzed by GO and KEGG, 221 showing that these genes were closely related to DNA replication, cell cycle, and p53 222 signaling pathways (Figure 1H, I). Furthermore, random forest algorithms showed 223 higher scores for the 15 genes with higher predictive values in the gene concentration 224 (Figure 1J). Overall, through a comprehensive analysis of multiple datasets, we 225 identified modules and genes that were closely related to UCEC, and they were 226 dramatically gathered in cell cycle-related pathways.

Figure 1. Identification of key gene modules in WGCNA. (A-B) The volcano map 227 228 of the DEGs screening from the TCGA-UCEC and GSE17025, GSE39099, and GSE106191 data sets. (C-D) GSEA analysis of DEGS. (E) WGCNA analysis 229 identified the module related to UCEC in the TCGA database as the yellow module (r 230 231 = 0.4). (F) WGCNA analysis confirmed the module most associated with UCEC in the GEO dataset as the yellow module (r = 0.42). (G) The Venn figure depicted the 232 TCGA-UCEC, GEO-UCEC intersection of related genes. (H, I) The GO and KEGG 233 pathway analysis of the gene set containing 164 genes. (J) The random forest 234 analysis. 235

236

237 LASSO regression analysis further built a diagnostic model containing 20 genes.

To build the predictive model and improve the accuracy of the prediction, we employed an LASSO regression analysis of the 164 genes. Then, we refined 20 core genes (Figure 2A, B). Simultaneously, they had higher levels of expression in cancer tissue than normal tissue (Figure 2C). Based on these key genes, we constructed a

diagnostic model whose ROC curve analysis AUC values reached 1, showing high
diagnostic accuracy (Figure 2D). GO and KEGG pathway analyses were used to
understand the biological functions of genes, showing that the genes were highly
concentrated in the pathways related to cell cycle regulation (Figure 2E).

Figure 2. A LASSO regression diagnosis model was constructed. (A-B) LASSO regression analysis was used to determine the most critical model genes, and a new gene set containing 20 genes was obtained. (C) Expression profiles of 20 genes. (D) Diagnostic ROC curves of key gene sets in UCEC. (E) GO and KEGG pathway enrichment analysis of gene sets.

251

252 Identification of molecular subtypes of endometrial cancer-related genes.

253 To study the biological differences between the different subtypes of UCEC, the ConsensusClusterPlus package was used to conduct a consistent clustering analysis of 254 the expression profiles of 20 model genes. CDF curve results showed that when k = 3, 255 256 the classification was dependable and steady (Figure 3A-C). Meanwhile, the specific expression of the 20 genes in the three clusters was presented in the hot chart (Figure 257 3D). Immediately, we compared the survival conditions of these three clusters (C1, 258 C2, and C3), suggesting that the C3 cluster had the worst prognostic effect and that 259 there were no significant differences between C2 and C1 (Figure 3E). Overall, there 260 may be some differences in prognosis between the different subtypes of these 261 262 UCEC-related genes.

Figure 3. Identification of the molecular subtypes of genes associated with endometrial cancer. (A-C) Consensus clustering determined three UCEC clusters with different enrichment scores. (D) A heat map depicting the expressions of 20 genes in the three clusters. (E) The UCEC OS curve of patients between different subtypes.

268

269 **DSN1** had the highest research value based on 20 gene survival analyses.

To explore the predictive and diagnostic value of the genes, we used R software to 270 271 map the survival curves. It indicated that the eight genes, such as DSN1, had a significant and strong correlation between their high levels of expression and the 272 patient's poor overall survival (OS), suggesting that they may be potential biological 273 274 markers for disease diagnosis and prognosis assessment (Figure 4A). In contrast, the results of the remaining 12 genes showed no statistically significant differences (as 275 shown in Supplementary Figure 1A). Furthermore, according to the random forest 276 chart score (Figure 1J), the DSN1 gene had the highest score, and its specific role in 277 UCEC had not yet been explored, which greatly aroused our interest. So we further 278 explored its potential biological function and its role in the cancer process. The 279 diagnostic ROC curve of DSN1 showed a high diagnostic value of AUC of 0.966 280 (Figure 4B). We further constructed a nomogram containing the parameters of the age 281 and different expressions for DSN1. And the calibration chart validates the calculated 282 scores that can accurately predict the 1-, 3-, and 5-year survival chances (Figure 4C, 283 D). 284

Figure 4. Survival analysis of model genes and identification of core genes. (A)

OS curves of model genes with statistically significant survival. (B) Diagnostic ROC curve of DSN1 expression in endometrial cancer. (C) Nomogram to predict 1-, 3-, or 5-year OS rates in patients with endometrial cancer. (D) Calibration curve of the nomogram.

290

291 DSN1 was associated with multiple clinical pathology characteristics in UCEC.

To explore the link between DSN1 and the clinical characteristics in UCEC, we 292 293 conducted gene expression and clinical pathological characteristics analysis. It showed the expression of DSN1 in tumor tissue was significantly higher (P < 0.001) 294 (Figure 5A, B). Next, we detected the links between gene expression and clinical 295 296 pathological characteristics. In terms of OS, significantly increased DSN1 was observed in UCEC-dead patients (P < 0.05) (Figure 5C). Meanwhile, vitally increased 297 DSN1 was observed in the group over 60 (Figure 5D). As the tumor developed, the 298 expression of DSN1 also increased significantly with the increase in histologic grade 299 (Figure 5E). In the clinical stage, DSN1 expression in Stage I was prominently lower 300 than that in Stage III (Figure 5F). Subsequently, we mapped the total survival curve 301 under different clinical pathological characteristics, assessing their prognosis and 302 diagnostic value. It demonstrated that the overall survival rate was lower with high 303 expression of DSN1 for a worse prognosis, no matter if the group was for different 304 ages (Figure 5G, H). The OS for patients with high expression of DSN1 was low in 305 prognosis at G1 and G2, while G3 was without significant differences (Figure 5I, J). 306

307 The OS for patients with high expression of DSN1 was low in prognosis at Stage I and Stage II, while at Stage III and Stage IV, there were no significant differences 308 (Figure 5K, L). The gRT-PCR was performed on the tumor tissues and corresponding 309 non-tumor tissues of 50 UCEC patients, and it showed that the mRNA expression 310 levels of 33 of these samples were significantly upregulated (Figure. 5M). According 311 312 to the results of WB, the experiment DSN1 protein levels were significantly increased in cancer tissue (Figure 5N, O). In conclusion, the expression of DSN1 was 313 significantly increased in cancer tissues, and its differential expression may have 314 different effects under different clinicopathological characteristics. 315

Figure 5. Correlation between DSN1 expression and clinicopathological features.

(A) DSN1 mRNA levels in tumor and normal tissues based on the TCGA database. 317 (B) Based on the TCGA database, DSN1 was differentially expressed in 318 UCEC-paired samples. The expression level of DSN1 under the different clinical 319 pathological features, including (C) OS event, (D) age, (E) histologic grade, and (F) 320 clinical stage (*p < 0.05, **p < 0.01, ***p < 0.001). The overall survival curves of 321 patients with differential DSN1 expression under different clinicopathological 322 characteristics include (G) age ≤ 60 , (H) age > 60, (I) histological grade: G1 and G2, 323 (J) histological grade: G3, (K) clinical stage: stage I and stage II, and (L) stage II 324 and stage IV. (M) Quantitative Real-time PCR analysis of DSN1 mRNA level in 50 325 cases of UCEC tissues and corresponding normal tissues. Left, a log 2 (T/N) value >0 326 indicated that DSN1 expression was overexpressed in the UCEC samples; right, a log 327 2 (T/N) value <0 indicated that DSN1 expression was downregulated in the UCEC 328

samples. (N,O) Determination and quantification of DSN1 protein levels in UCEC
 tissues and paired non-tumor tissues by western blot.

331

332 Exploring the potential biological functions of DSN1 in UCEC

To study the biological significance of DSNI in UCEC, we found DSN1 333 co-expression genes (Figure 6A). The hot charts, respectively, showed the top 50 334 genes that were positively and negatively related to DSN1 (Figure 6B, C). Then, we 335 explored the potential pathways for DSN1 in UCEC. GO analysis suggested that 336 337 when DSN1 expression was elevated, pathways such as DNA replication were activated (Figure 6D). KEGG analysis showed that when DSN1 expression was 338 elevated, pathways such as the cell cycle, DNA replication, and pyrimidine 339 340 metabolism were activated (Figure 6E). Meanwhile, GSEA analysis indicated that the elevation of DSN1 expression was closely related to pathways such as the cell cycle, 341 DNA replication, and purine metabolism (Figure 7A-I), showing that DSN1 can affect 342 cell cycle-related pathways. 343

Figure 6. Using Linkedomics to investigate potential biological processes in
which DSN1 was involved. (A) Volcano plot of DSN1 co-expressed genes. (B, C)

346 UCEC DSN1 top 50 positive correlation and negative correlation gene heat maps. (D,

E) GO and KEGG pathway enrichment analysis of DSN1 in endometrial carcinoma.

Figure 7. GSEA pathway enrichment analysis. Using GSEA, we found that DSN1

349 participated in potential biological processes, including (A) cell cycle, (B) DNA

350 replication, (C) basal transcription factors, (D) purine metabolism, (E) P53 signaling

pathway, (F) regulation of autophagy, (G) nucleotide excision repair, (H) mismatch
repair, and (I) RNA polymerase.

353

354 Construction of PPI networks associated with DSN1

Protein interactions play an irreplaceable role in life processes such as cell cycle 355 regulation. To study the specific mechanisms of DSN1 in cell cycles, we built a 356 network of DNS1 protein interactions (Figure 8A). The first 50 genes of the 357 interaction were shown in Figure 8B. We then screened the top 10 genes of the PPI 358 359 score for a correlation and survival analysis, showing that all 10 were significantly positive, but only 6 of them had statistically significant survival (Figure 8C, D 360 (Supplementary Figure 2A, B)). Among them, NDC80 has the highest correlation 361 362 with DSN1, and NDC80 is highly expressed in a variety of cancers, such as liver cancer (13) and epithelial ovarian cancer (14). In addition, NDC80 can also promote 363 the progression of glioma by affecting the cell cycle (15). Therefore, we speculate 364 that DSN1 can influence the UCEC progression by influencing NDC80. WB revealed 365 that NDC80 and Cyclin D1 protein levels dropped when DSN1 was knocked down 366 (Figure 8E). As a result, we postulated that DSN1 may contribute to cancer 367 progression by regulating NDC80 to stimulate the cell cycle. 368

Figure 8. The establishment of the DSN1-related protein-protein interaction network and the analysis of the hub genes. (A, B) DSN1-associated protein-protein interaction (PPI) network. (C) Correlation between DSN1 and the expression of NDC80, SPC25, BUB1, CENPA, BUB1B, and CENPI in UCEC. (D) Prognostic

analysis of related genes. (E) Western blot was used to detect DSN1, NDC80, and
Cyclin D1 protein expression in UCEC cells stably transfected with the control
shRNA or the DSN1 shRNA.

376

377 Relevance of DSN1 expression to immune cell infiltration

To reveal the relationship between DSN1 expression and the UCEC immune 378 response, the immune microenvironment was analyzed between the DSN1 differential 379 expression groups. Multiple immune cells in the DSN1 low-expression group were 380 381 significantly enriched. For the DSN1 high-expression group, the enrichment of T helper cells, Tgd cells, and Th2 cells was higher (Figure 9A). Simultaneously, it 382 demonstrated that DSN1 was negatively related to the vast majority of immune cells. 383 while it was remarkably positive for Th2 cells, T helper cells, TGD, and Tcm (Figure 384 9B). Next, we delved into the relationship between DSN1 expression and immune 385 infiltration. It revealed that DSN1 expression was negatively associated with the 386 immune cell infiltration of B cells, CD4+ T cells, and dendritic cells. However, there 387 was a positive correlation with neutrophils and no statistical significance for CD8+T 388 cells and macrophages (Figure 9C). Then, it was found that DSN1 expression was 389 negatively correlated with most chemokines and significantly positively correlated 390 with CCL7 and CCL8 expression in UCEC (Figure 9D, E, F). Furthermore, the Th2 391 cells and chemokines CCL7 and CCL8 were significantly positively related (Figure 392 9G, H). Overall, DSN1 may affect the enrichment of Th2 cells in UCEC. 393

medRxiv preprint doi: https://doi.org/10.1101/2024.11.27.24318050; this version posted November 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

(which was not certified by peer review) is the addite	ninder, who has granice means a needs to dis
De	
	ipolary.
It is made available under a	CC-BY 4.0 International license.

394	Figure 9. Analysis of the correlation between the DSN1 expression and the
395	immune level and the chemokines. (A) Box plots showed the differences in immune
396	microenvironment between DSN1 high and low expression groups. (B) The lollipops
397	of the correlation of DSN1 expression and immune cells. (C) Correlation of DSN1
398	expression in UCEC with infiltration levels of B cell, CD8+ T cell, CD4+ T cell,
399	macrophage, neutrophil, and dendritic cell. (D) Heat map of the correlation between
400	DSN1 expression and chemokines in pan-cancer. (E, F) Scatter plot of the correlation
401	between CCL7, CCL8, and DSN1 expression. (G, H) Scatter plots of the correlation
402	between CCL7 and CCL8 expression and Th2 cell enrichment.
403	

DSN1 drug interaction and drug sensitivity analysis 404

405 To explore interactions of DSN1 and cancer treatment drugs, we established drug interaction networks. It showed that seven kinds of drugs could promote the 406 expression of DSN1. However, 11 drugs could inhibit the expression of DSN1 (Figure 407 10A). We compared cgp2014 and CTD, and cisplatin and sunitinib were found in 408 both them (Figure 10B). IC50 results showed that, when DSN1 had high expression, 409 the cisplatin IC50 was lower, and the sunitinib IC50 was higher than that when DSN1 410 had low expression (Figure 10C-D). Moreover, it indicated that when DSN1 was 411 highly expressed, the patients were sensitive to cisplatin and were resistant to 412 sunitinib. 413

Figure 10. Gene-drug interactions and drug-susceptibility analyses. (A) CTD 414 showed the interaction network between DSN1 and the drug. (B) The Venn figure 415

showed the drug sensitivity results from the two databases. (C-D) The box plots
showed the cisplatin IC50 and sunitinib IC50 of DSN1 differential expression.

418

419 **Discussion**

Endometrial cancer is one of the most prevalent gynecologic malignancies in 420 developed nations. The incidence rate of UCEC in China was 10.54/100,000, and the 421 fatality rate was 2.53/100,000, based on data from the National Cancer Center for the 422 year 2022 (16). In addition, due to the increasing prevalence of obesity and metabolic 423 424 syndrome, the incidence and mortality of UCEC are still increasing significantly (17). While most patients with early-stage UCEC can be cured with hysterectomy and 425 adjuvant radiotherapy, the prognosis remains poor for patients with late-stage UCEC, 426 with a five-year survival rate of roughly 48% for stage III and 15% for stage IV (18). 427 However, there are currently no biomarkers for the routine clinical diagnosis and 428 prognosis of UCEC (19), so finding new, reliable biomarkers for UCEC and learning 429 more about its molecular biology are urgently needed. In this study, we created a 430 diagnostic model for UCEC by combining multiple databases for comprehensive 431 bioinformatics analysis and experimental verification. We also revealed the 432 expression level and prognostic significance of the key gene DSN1 in the model in 433 UCEC and further explored the biological mechanism of DSN1 promoting the 434 occurrence and progression of UCEC. 435

In this study, we combined three endometrial cancer mRNA microarray datasets from the GEO database (GSE17025, GSE39099, and GSE106191) and the

endometrial cancer datasets from the TCGA database for differential gene analysis. 438 We then performed WGCNA analysis of these differential genes and obtained 164 439 440 core genes that were significantly associated with UCEC in both databases. Then, through pathway enrichment analysis, we found that these 164 core genes were 441 substantially enriched in cell cycle-related pathways, such as mitotic cell cycle 442 transition, regulation of cell cycle transition, DNA replication, and other signaling 443 pathways. At the same time, through random forest analysis, the top 15 genes with the 444 highest score among 164 core genes were found. We then performed lasso regression 445 446 analysis on these 164 genes and obtained 20 core genes for UCEC diagnosis. In addition, we also used consensus cluster analysis to divide UCEC into three major 447 subtypes based on these 20 genes and constructed associated prognostic models. 448

449 Then, through the survival analysis of these 20 genes and taking into account the random forest algorithm mentioned above, DSN1 can influence patient prognosis in 450 addition to having a major impact on the random forest algorithm. At the same time, 451 DSN1, as a kinetochore protein-coding gene, is widely distributed in centromere (20) 452 and is crucial for preserving the stability of centromere structure and proper 453 chromosome separation (10). Previous studies have shown that DSN1 can alter the 454 cell cycle, which can accelerate the growth of certain malignancies. For example, in 455 colorectal cancer, DSN1 can be stabilized in an M6A-related manner that promotes 456 cancer progression (21); in breast cancer, DSN1 expression is significantly 457 upregulated and is strongly linked to a poor prognosis and decreased survival (7). 458 However, the expression of DSN1 in endometrial cancer and its biological function 459

remain unclear. Our investigation revealed a correlation between the prognosis and 460 expression level of DSN1 and several clinicopathological characteristics of UCEC, 461 462 such as age, histological grade, and clinical stage. Further, we also confirmed that the expression of DSN1 in endometrial carcinoma tissues was greater than that in normal 463 control tissues by qRT-PCR and western blot, which was consistent with 464 bioinformatics analysis. In summary, DSN1's mRNA and protein levels in UCEC 465 have changed, but more research is still needed to determine the precise mechanism of 466 action. 467

468 In order to further reveal the specific biological mechanism of DSN1 affecting UCEC, we conducted the enrichment analysis of the GOKEGG pathway and the 469 GSEA pathway. The outcomes demonstrated that DSN1 was considerably activated in 470 471 cell cycle, DNA replication, chromosome separation, and other pathways. It is well known that cell cycle is one of the main cellular mechanisms influencing the 472 development of malignant tumors (22) and having a significant impact on metastasis, 473 immunity, and tumor metabolism (23). The high expression of DSN1 in UCEC may 474 promote the growth of tumor cells by influencing the cell cycle. We further verified 475 this hypothesis through experiments. The experimental results demonstrated that 476 Cyclin D1 protein level decreased following DSN1 knockdown. These results suggest 477 that DSN1 knockdown can inhibit the cell cycle, thereby inhibiting tumor growth. In 478 summary, our study revealed that DSN1 is likely to promote cell proliferation and 479 cancer progression in UCEC by promoting the UCEC cell cycle. 480

481 Subsequently, through PPI analysis, we found that DSN1 had protein interaction

with NDC80, SPC25, BUB1, CENPA, BUB1B, and CENPI. Among them, NDC80 is 482 the gene with the highest correlation with DSN1, and as the outer component of the 483 484 centromere and the regulator of spindle check points, NDC80 is highly expressed in a variety of cancers. NDC80 knockdown in pancreatic cancer can cause cell cycle halt, 485 which slows tumor development (24). NDC80 knockdown in gastric cancer can 486 significantly reduce cell growth in vitro and in vivo, preventing cell division during 487 the G2/M phase (25). Furthermore, research has shown that NDC80 is significantly 488 overexpressed in endometrial cancer and is associated with a poor prognosis (26). 489 490 Thus, we hypothesize that DSN1's interaction with NDC80 may have an impact on the onset and progression of UCEC. Through experiments, we found that in the 491 shDSN1 group, NDC80 and Cyclin D1 protein levels were significantly reduced. 492 493 Through these experiments, we have reason to believe that DSN1 affects the cell cycle through NDC80 and thus mediates the incidence and growth of tumors. 494

Given the growing body of research demonstrating the pivotal role the tumor 495 496 microenvironment plays in tumor initiation, development, metastasis, and response to therapy (27), we looked at the relationship between DSN1 expression and immune 497 cell infiltration in UCEC. The results demonstrated a negative correlation between 498 DSN1 expression and the majority of immune cells' infiltration abundance and a 499 positive correlation with Th2 cells' infiltration abundance. Th2 cells have the function 500 of promoting tumor progression and immunosuppression, which is often linked to a 501 poor prognosis of various tumors (28), and Th1/Th2 balance restoration is crucial in 502 the therapy of cancers (29). Then, we examined the chemokines linked to DSN1 503

expression to look into the connection between DSN1 and immune cell infiltration in 504 more detail. The findings demonstrated that DSN1 was negatively correlated with 505 506 most chemokines in UCEC but positively correlated with CCL7 and CCL8. And CCL7 and CCL8 were also positively correlated with Th2 cells in UCEC. According 507 to previous studies, CCL7 can enrich Th2 cells during scar formation, thus affecting 508 the local expression levels of Th1 and Th2 cells (30). In vitiligo, CCL8 can deflect T 509 cells toward pathogenic Th2 cells (31). Therefore, we speculate that DSN1 is likely to 510 affect the infiltration level of Th2 cells by regulating CCL7 and CCL8, thus 511 512 promoting tumor progression and immunosuppression. In summary, taking advantage of the properties of DSN1 that may increase the proportion of Th2 cells, it is possible 513 to try to combine DSN1 inhibitors with immune checkpoint inhibitors to further 514 515 enhance the effect of immunotherapy in UCEC patients.

In conclusion, our study integrated various bioinformatics approaches across 516 multiple datasets to ultimately establish a diagnostic and prognostic model for UCEC, 517 in which DSN1 is expected to be a biomarker for early diagnosis and treatment of 518 endometrial cancer. Bioinformatics analysis and experiments confirmed that DSN1 519 was overexpressed in UCEC and correlated with some clinicopathological features. 520 At the same time, we also tested how DSN1 affects the cell cycle through 521 experiments. Finally, we proposed and predicted the interaction of DSN1 with 522 NDC80, as well as analyzed drugs that were sensitive to cells with high DSN1 523 524 expression.

525 However, we need to acknowledge several limitations related to this study. First,

526	we obtained data on UCEC mainly from online public databases, and larger studies
527	are still needed in the future to validate and strengthen our findings. Secondly, we
528	only verified the interaction of DSN1 with NDC80 and did not further verify their
529	specific mode of action through experiments.
530	
531	Acknowledgements
532	We thank the mentioned public databases for providing us the data and analytical
533	tools.
534	
535	Reference
536	1. Zheng W. Molecular Classification of Endometrial Cancer and the 2023
537	FIGO Staging: Exploring the Challenges and Opportunities for Pathologists.
538	CANCERS. [Journal Article]. 2023 2023/8/15;15(16).
539	2. Ogunmuyiwa J, Williams V. Emerging Advances in Endometrial Cancer:
540	Integration of Molecular Classification into Staging for Enhanced Prognostic
541	Accuracy and Implications for Racial Disparities. CANCERS. [Journal Article;
542	Review]. 2024 2024/3/16;16(6).
543	3. Dobrzycka B, Terlikowska KM, Kowalczuk O, Niklinski J, Kinalski M,
544	Terlikowski SJ. Prognosis of Stage I Endometrial Cancer According to the FIGO
545	2023 Classification Taking into Account Molecular Changes. CANCERS. [Journal
546	Article]. 2024 2024/1/17;16(2).
547	4. Coll-de LRE, Martinez-Garcia E, Dittmar G, Gil-Moreno A, Cabrera S,

548	Colas E. Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and
549	Meta-Analysis. J CLIN MED. [Journal Article; Review]. 2020 2020/6/17;9(6).
550	5. Chen J, Wu S, Wang J, Han C, Zhao L, He K, et al. MCM10: An effective
551	treatment target and a prognostic biomarker in patients with uterine corpus
552	endometrial carcinoma. J CELL MOL MED. [Journal Article; Research Support,
553	Non-U.S. Gov't]. 2023 2023/6/1;27(12):1708-24.
554	6. Ayodele A, Obeng-Gyasi E. Exploring the Potential Link between PFAS
555	Exposure and Endometrial Cancer: A Review of Environmental and

556 Sociodemographic Factors. CANCERS. [Journal Article; Review]. 2024 557 2024/2/28;16(5).

7. Peng Q, Wen T, Liu D, Wang S, Jiang X, Zhao S, et al. DSN1 is a prognostic
biomarker and correlated with clinical characterize in breast cancer. INT
IMMUNOPHARMACOL. [Journal Article]. 2021 2021/12/1;101(Pt B):107605.

8. Chuang TP, Wang JY, Jao SW, Wu CC, Chen JH, Hsiao KH, et al.
 Over-expression of AURKA, SKA3 and DSN1 contributes to colorectal adenoma to
 carcinoma progression. Oncotarget. [Journal Article]. 2016
 2016/7/19;7(29):45803-18.

565 9. Li FN, Zhang QY, Li O, Liu SL, Yang ZY, Pan LJ, et al. ESRRA promotes
566 gastric cancer development by regulating the CDC25C/CDK1/CyclinB1 pathway
567 via DSN1. INT J BIOL SCI. [Journal Article; Research Support, Non-U.S. Gov't].
568 2021 2021/1/20;17(8):1909-24.

569 10. Sun C, Huang S, Ju W, Hou Y, Wang Z, Liu Y, et al. Elevated DSN1

expression is associated with poor survival in patients with hepatocellular
carcinoma. HUM PATHOL. [Journal Article; Research Support, Non-U.S. Gov't].
2018 2018/11/1;81:113-20.

Li Q, Liang J, Chen B. Identification of CDCA8, DSN1 and BIRC5 in 11. 573 574 Regulating Cell Cycle and Apoptosis in Osteosarcoma Using Bioinformatics and Cell Biology. TECHNOL CANCER RES Τ. [Journal Article]. 2020 575 2020/1/1;19:1079233253. 576

Huang D, Xiao F, Hao H, Hua F, Luo Z, Huang Z, et al. JARID1B promotes
colorectal cancer proliferation and Wnt/beta-catenin signaling via decreasing CDX2
level. CELL COMMUN SIGNAL. [Journal Article; Research Support, Non-U.S.
Gov't]. 2020 2020/10/27;18(1):169.

13. Huang M, Yang S, Tai W, Zhang L, Zhou Y, Cho W, et al. Bioinformatics
Identification of Regulatory Genes and Mechanism Related to Hypoxia-Induced
PD-L1 Inhibitor Resistance in Hepatocellular Carcinoma. INT J MOL SCI. [Journal
Article]. 2023 2023/5/13;24(10).

Yu X, Pan M, Jiang L, Liu K. NDC80 Kinetochore Complex Serves as a 14. 585 Correlates with Immune Infiltrates in Epithelial Potential Prognostic Predictor and 586 Ovarian Patients. INT J GEN MED. [Journal Article]. 587 Cancer 2024 2024/1/20;17:1789-805. 588

Ye W, Liang X, Chen G, Chen Q, Zhang H, Zhang N, et al. NDC80/HEC1
promotes macrophage polarization and predicts glioma prognosis via single-cell
RNA-seq and in vitro experiment. CNS NEUROSCI THER. [Journal Article]. 2024

592 2024/7/1;30(7):e14850.

Li W, Xu Y, Zeng X, Tan J, Wang Y, Wu H, et al. Etiological relationship 593 16. between lipid metabolism and endometrial carcinoma. LIPIDS HEALTH DIS. 594 [Journal Article; Review]. 2023 2023/8/4;22(1):116. 595 Sung H. Ferlav J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. 596 17. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality 597 Worldwide for 36 Cancers in 185 Countries. CA-CANCER J CLIN. [Journal Article]. 598 2021 2021/5/1;71(3):209-49. 599 600 18. Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. LANCET. [Journal Article; Research Support, Non-U.S. 601 Gov't; Review]. 2022 2022/4/9;399(10333):1412-28. 602 603 19. Behrouzi R, Barr CE, Crosbie EJ. HE4 as a Biomarker for Endometrial Cancer. CANCERS. [Journal Article; Review]. 2021 2021/9/23;13(19). 604 Navarro-Mendoza MI, Perez-Argues C, Panchal S, Nicolas FE, Mondo SJ, 20. 605 Ganguly P, et al. Early Diverging Fungus Mucor circinelloides Lacks Centromeric 606 Histone CENP-A and Displays a Mosaic of Point and Regional Centromeres. 607 CURR BIOL. [Journal Article; Research Support, N.I.H., Extramural; Research 608 Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.]. 2019 609 2019/11/18;29(22):3791-802. 610

Wang X, Lu X, Wang P, Chen Q, Xiong L, Tang M, et al. SRSF9 promotes
colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related
manner. J TRANSL MED. [Journal Article]. 2022 2022/5/4;20(1):198.

614	22. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer.
615	NATURE. [Journal Article; Review]. 2001 2001/5/17;411(6835):342-8.
616	23. Cheung AH, Hui CH, Wong KY, Liu X, Chen B, Kang W, et al. Out of the
617	cycle: Impact of cell cycle aberrations on cancer metabolism and metastasis. INT J
618	CANCER. [Journal Article; Research Support, Non-U.S. Gov't; Review]. 2023
619	2023/4/15;152(8):1510-25.
620	24. Meng QC, Wang HC, Song ZL, Shan ZZ, Yuan Z, Zheng Q, et al.
621	Overexpression of NDC80 is correlated with prognosis of pancreatic cancer and
622	regulates cell proliferation. AM J CANCER RES. [Journal Article]. 2015
623	2015/1/20;5(5):1730-40.
624	25. Qu Y, Li J, Cai Q, Liu B. Hec1/Ndc80 is overexpressed in human gastric
625	cancer and regulates cell growth. J GASTROENTEROL. [Journal Article; Research
626	Support, Non-U.S. Gov't]. 2014 2014/3/1;49(3):408-18.

26. Chen Y, Yao Y, Zhang L, Li X, Wang Y, Zhao L, et al. cDNA microarray
analysis and immunohistochemistry reveal a distinct molecular phenotype in serous
endometrial cancer compared to endometrioid endometrial cancer. EXP MOL
PATHOL. [Comparative Study; Journal Article; Research Support, Non-U.S. Gov't].
2011 2011/8/1;91(1):373-84.

27. Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer.
PHARMACOL THERAPEUT. [Journal Article; Research Support, N.I.H.,
Extramural; Research Support, Non-U.S. Gov't; Review]. 2021 2021/5/1;221:107753.
Palucka AK, Coussens LM. The Basis of Oncoimmunology. CELL. [Journal

636	Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't;
637	Research Support, U.S. Gov't, Non-P.H.S.; Review]. 2016 2016/3/10;164(6):1233-47.
638	29. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC. Predominant
639	Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J
640	IMMUNOL. [Journal Article; Research Support, Non-U.S. Gov't]. 2001
641	2001/9/1;167(5):2972-8.
642	30. Chen B, Li H, Xia W. Imiquimod regulating Th1 and Th2 cell-related
643	chemokines to inhibit scar hyperplasia. INT WOUND J. [Journal Article]. 2019
644	2019/12/1;16(6):1281-8.
645	31. Jin R, Zhou M, Lin F, Xu W, Xu A. Pathogenic Th2 Cytokine Profile
646	Skewing by IFN-gamma-Responding Vitiligo Fibroblasts via CCL2/CCL8.
647	CELLS-BASEL. [Journal Article; Research Support, Non-U.S. Gov't]. 2023
648	2023/1/4;12(2).
649	
650	Supplementary Figure captions

Supplementary Figure 1. The survival curves of 12 genes for which they were not
 statistically significant. (A) 12 genes with no statistically significant survival curves.

653 Supplementary Figure 2. Correlation analysis and survival analysis of four genes

for which survival analysis was not meaningful. The correlation scatter plot for
genes without survival statistical significance for (A) AURKB, MAD2L1, NUF2, and
ZWINT. The survival curves of the genes include (B) AURKB, MAD2L1, NUF2, and
ZWINT.



















B



E



D

G

0.0

-0.5

0

Figure 7





Enrichment plot: KEGG_P53_SIGNALING_PATHWAY

-0.1 al 2N 1.0 8 0.5 0.0 3 -0.5 10,000

F

Enrichment plot: KEGG_REGULATION_OF_AUTOPHAGY



Enrichment plot: 0.8 Errichment score (ES) Ranked list metric (Signal2Noise) 1.0 0.5















Type BDSN1 high expression BDSN1 low expression